REDWOOD CITY, CA and NEW YORK, NY--(Marketwired - September 26, 2013) - BioCentury will convene the 20th Annual NewsMakers in the Biotech Industry in New York City this Friday, September 27, at 8 a.m. at the Millennium Broadway Hotel & Conference Center.
The event showcases 48 publicly traded biopharma companies independently selected on the basis of key clinical, regulatory and commercial milestones that will drive valuations going into 2014. More than 600 life science investment professionals and pharmaceutical business development and licensing executives have pre-registered for the event.
Online registration has closed, but on-site registration is available at the Millennium Broadway starting at 7:15 a.m. on September 27.
The 2013 NewsMakers Presenting Companies
The presenting companies represent an independently selected mix of biotechs with near-term commercial, regulatory and clinical milestones. They were screened using BioCentury's industry analysis and BCIQ online business intelligence platform.
The 2013 NewsMakers are outpacing the biotech bull market. The aggregate market cap of the NewsMakers companies has jumped this year from $23.6 billion to $39.8 billion through August. This is a 69% increase, compared with a 48% gain in the BioCentury 100 Index and a 53% gain in the NASDAQ Biotechnology Index (NBI). Investors also have poured more than $4.7 billion into the Class of 2013 since the beginning of 2012, including nearly $2.5 billion this year.
"Biotech is in the midst of a record 5 year run, outpacing the key equity indices, including the Dow Jones Industrials, the S&P 500 and the NASDAQ Biotechnology Index," said BioCentury Publisher Eric Pierce. "Members of the NewsMakers Class of 2013 have played a significant role in drawing investors into the biotech space. We're pleased to have the opportunity to showcase them and their upcoming, near-term milestones to the investment community at NewsMakers."
The NewsMakers pipeline is robust with both partnered and unpartnered programs that should be of interest to pharma business development and licensing professionals. The group has more than 50 products on the market, and nine compounds under regulatory review, including three with near-term PDUFA dates. The group is conducting more than 250 clinical trials, including 35 Phase III trials and more than 140 Phase II trials across key disease areas including cancer, infectious diseases, inflammation, cardiovascular and autoimmune disorders. The NewsMakers assets include more than 225 unpartnered programs, with more than 140 of them in the clinic and 70 in preclinical/IND stages.
NewsMakers 2013 Class of Presenting Companies (NASDAQ listed unless otherwise noted)
Alnylam Pharmaceuticals Inc. (ALNY)
AMAG Pharmaceuticals Inc. (AMAG)
Ambit Biosciences Corp. (AMBI)
Arena Pharmaceuticals Inc. (ARNA)
Array BioPharma Inc. (ARRY)
BioMarin Pharmaceutical Inc. (BMRN)
Cempra Inc. (CEMP)
Chelsea Therapeutics International Ltd. (CHTP)
ChemoCentryx Inc. (CCXI)
Chimerix Inc. (CMRX)
Cytokinetics Inc. (CYTK)
Cytos Biotechnology AG (CYTN)
Durect Corp. (DRRX)
Epizyme Inc. (EPZM)
Esperion Therapeutics Inc. (ESPR)
Exelixis Inc. (EXEL)
Galectin Therapeutics Inc. (GALT)
Galena Biopharma Inc. (GALE)
Halozyme Therapeutics Inc. (HALO)
Horizon Pharma Inc. (HZNP)
ImmunoCellular Therapeutics Ltd. (IMUC)
Inovio Pharmaceuticals Inc. (INO)
KaloBios Pharmaceuticals Inc. (KBIO)
Keryx Biopharmaceuticals Inc. (KERX)
The Medicines Co. (MDCO)
MEI Pharma Inc. (MEIP)
Mesoblast Ltd. (MSB; MBLTY)
Navidea Biopharmaceuticals Inc. (NAVB)
Nektar Therapeutics (NKTR)
NeoStem Inc. (NBS)
NewLink Genetics Corp. (NLNK)
NPS Pharmaceuticals Inc. (NPSP)
Omeros Corp. (OMER)
OncoMed Pharmaceuticals Inc. (OMED)
Orexo AB (ORX)
Organovo Holdings Inc. (ONVO)
Portola Pharmaceuticals Inc. (PTLA)
Prosensa Holding N.V. (RNA)
Receptos Inc. (RCPT)
Repros Therapeutics Inc. (RPRX)
Resverlogix Corp. (RVX)
SciClone Pharmaceuticals Inc. (SCLN)
Sucampo Pharmaceuticals Inc. (SCMP)
Sunesis Pharmaceuticals Inc. (SNSS)
TG Therapeutics Inc. (TGTX)
TherapeuticsMD Inc. (TXMD)
Verastem Inc. (VSTM)
Ziopharm Oncology Inc. (ZIOP)
See the Presenting Company schedule and additional program highlights at http://www.biocentury.com/Data/NewsCenter2/Conferences/ConferencesFiles/NM13schedule.pdf.
Sponsors Demonstrate Long-Term Commitment to Industry
The NewsMakers 2013 sponsors are anchored by Gold Sponsors Brinson Patrick, L.E.K Consulting LLC, and WBB Securities LLC. They are joined by Silver Sponsor AstraZeneca plc.
Future BioCentury Conferences
NewsMakers is one of two premier investor conferences organized annually by BioCentury in New York. The next conference, the 21st Future Leaders in the Biotech Industry, will take place in New York City on March 28, 2014. Future Leaders connects leading portfolio managers, bankers, analysts and business development professionals with investor-validated, milestone-rich private and public companies in key therapeutic areas.
BioCentury also is a co-organizer of the upcoming SciBX Summit on Innovation in Drug Discovery & Development, to be held in Boston on October 30, 2013. The SciBX Summit is a groundbreaking conference that brings together key stakeholders from academia, biotech, pharma and the investment community to create roadmaps for solving critical translational issues in important emerging areas of drug discovery and development. This year's conference will spotlight epigenetics, CAR-based cellular therapies, non-coding RNAs and new models and in neurological disease. For more information and to register, please go to http://www.biocentury.com/conferences/scibxsummit/dates.
BioCentury also co-organizes BioEUR quity Europe, which will take place in Amsterdam, May 21 - 22, 2014. BioEUR quity Europe is the premier event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for business development and licensing professionals from pharmaceutical companies to assess top partnering and licensing prospects.
Since 1993, BioCentury Publications, Inc. has provided essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators and public policy makers, and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia.
BioCentury's titles include the flagship BioCentury®, the Bernstein Report on BioBusiness; its SciBX: Science-Business eXchange™ translational science partnership with Nature Publishing Group; and its BioCentury Extra™ online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence™, an online business intelligence resource. BioCentury also produces its BioCentury This Week healthcare public affairs television program in partnership with the Gannett-owned WUSA CBS affiliate in Washington, D.C. The program is aired in the nation's capital every week as part of the WUSA*9 Sunday Morning Power Block, on Public Broadcasting System member stations in selected markets and is always available globally online at www.biocenturytv.com.
For more information, visit www.biocentury.com and www.biocenturytv.com.